Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-117 in Primary Open-angle Glaucoma or Ocular Hypertension
NCT02179008Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omidenepag isopropyl in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Jun 2014; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02179008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179008.